Altria Narrows 2026 Earnings Guidance, Raising the Low End
Altria narrowed its 2026 earnings guidance to $5.61-$5.72 adjusted EPS on July 30, 2026, lifting the low end. Our analysis of volumes, capex and the outlook.
The news
Altria Group narrowed its full-year earnings guidance on July 30, 2026, alongside its second-quarter and first-half results. The company said it now expects 2026 adjusted diluted EPS of $5.61 to $5.72, representing growth of 3.5% to 5.5% from a 2025 base of $5.42. The release described the move as raising the lower end of the range.
Second-quarter net revenues were $6.111 billion, up 0.1% from a year earlier. Revenues net of excise taxes rose 1.2% to $5.356 billion. Reported diluted EPS fell 2.8% to $1.37, while adjusted diluted EPS rose 2.8% to $1.48.
Volumes continued to decline. Cigarette shipments totaled 15.6 billion units, down 3.2%, and oral tobacco shipments fell 8.5% to 181.7 million cans.
In the first half of the year, Altria paid $3.6 billion in dividends and repurchased 5.3 million shares for $335 million, at an average price of $62.78.
Several factors were listed as shaping the outlook: moderating growth in the e-vapor category, macroeconomic uncertainty affecting adult nicotine consumers, investment tied to consolidating USSTC manufacturing facilities, and the expectation that NJOY ACE will not return to market in 2026. Capital expenditure guidance rose to $375 million to $450 million from $300 million to $375 million.
Our analysis
Narrowing guidance by raising only the floor is a modest but deliberate statement. It tells investors that management sees less downside risk than it did earlier in the year, without committing to a higher ceiling. For a company whose core volumes are shrinking, that distinction matters. The message is about predictability rather than acceleration.
The second-quarter numbers show how Altria generates earnings growth from declining units. Cigarette shipments fell 3.2%, yet revenues net of excise taxes rose 1.2% and adjusted EPS grew 2.8%. That spread reflects pricing and cost management offsetting volume losses, a pattern long familiar to followers of the tobacco sector. The guidance range of 3.5% to 5.5% growth implies that management expects this dynamic to continue for the rest of the year.
The oral tobacco decline of 8.5% stands out more than the cigarette figure. Oral products are often presented as part of the transition away from combustible cigarettes, so a sharper drop there is a reason to read the smoke-free strategy commentary carefully.
The capex increase is the clearest new cost signal in the release. Raising the range by $75 million at both ends, tied in part to the USSTC facility consolidation, points to a period of investment that could weigh on free cash flow in the near term even as it is meant to improve efficiency later.
The divergence between reported EPS, down 2.8%, and adjusted EPS, up 2.8%, is a reminder that special items moved in opposite directions this quarter. Anyone building an earnings analysis around the adjusted figure should review the reconciliation tables.
Room for disagreement
A bullish reading would emphasize that raising the low end of guidance midway through the year is uncommon for a mature company and signals confidence. The steady dividend outlay of $3.6 billion in six months underlines that capital return remains intact.
A more cautious reading would note that the top of the range did not move and that the outlook leans on pricing against shrinking volumes. The listed headwinds, particularly consumer uncertainty and slower e-vapor growth, are external factors Altria does not control. The absence of NJOY ACE for the rest of 2026 also limits one avenue for growth in smoke-free products.
The release also did not state the previous range in its headline guidance language, so the size of the narrowing must be confirmed against earlier filings.
What to watch
- Cigarette and oral tobacco shipment trends in the third quarter.
- Whether pricing continues to offset volume declines enough to keep adjusted EPS within the range.
- Capital spending against the raised $375 million to $450 million range.
- Any update on NJOY and the e-vapor category.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.